Regulation of PD-L1 expression in the tumor microenvironment
Open accessAbstract
Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune response. In this context, blocking PD-1/PD-L1 could restore T cells from exhausted status and eradicate cancer cells. However, only a subset of PD-L1 positive patients benefits from α-PD-1/PD-L1 therapies. Actually, PD-L1 expression is regulated by various factors, leading to the diverse significances of PD-L1 positivity. Understanding the mechanisms of PD-L1 regulation is helpful to select patients and enhance the treatment effect. In this review, we focused on PD-L1 regulators at the levels of transcription, post-transcription, post-translation. Besides, we discussed the potential applications of these laboratory findings in the clinic.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Activated EGFR signaling contributes to upregulated PD-L1 on cancer cells.
“Besides, activated EGFR signaling contributes to the upregulated PD-L1 on cancer cells, and EGFR-TKI might cooperate with α-PD-1/PD-L1 to attenuate immune evasion [188].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [188]
EGFR-TKI might cooperate with α-PD-1/PD-L1 to attenuate immune evasion.
“Besides, activated EGFR signaling contributes to the upregulated PD-L1 on cancer cells, and EGFR-TKI might cooperate with α-PD-1/PD-L1 to attenuate immune evasion [188].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [188]
Epigenetic alterations such as histone acetylation regulate PD-L1 expression.
“Epigenetic alterations such as histone acetylation regulate PD-L1 expression [188].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [188]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · see citing works
Self-citationNivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101 · see citing works
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280 · see citing works
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,564 · see citing works
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395 · see citing works
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390 · see citing works
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836 · see citing works
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,187 · see citing works
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942 · see citing works
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,465 · see citing works
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403 · see citing works
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric‐Bernstam, F., Qiao, N., Wu, Y., Harrington, S. M., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akçakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,394 · see citing works
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,394 · see citing works
Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337 · see citing works
Gainor, J. F., Shaw, A. T., Sequist, L. V. D., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L. E., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,256 · see citing works
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,237 · see citing works
Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D. V. T., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B. A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00175-3 · Cited by 1,117 · see citing works
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li, C., Lim, S., Xia, W., Lee, H., Chan, L.-C., Kuo, C., Khoo, K., Chang, S.-S., Cha, J., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,100 · see citing works
Chung, H. C., Ros, W., Delord, J., Perets, R., Italiano, A., Shapira‐Frommer, R., Manzuk, L., Piha-Paul, S. A., Xu, L., Zeigenfuss, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01265 · Cited by 1,075 · see citing works
Self-citationMechanisms Controlling PD-L1 Expression in Cancer
Cha, J., Chan, L.-C., Li, C., Hsu, J. L., & Hung, M. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.030 · Cited by 1,054 · see citing works
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013 · see citing works
Chen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y., Byers, L. A., Zhang, X., Yi, X., Dwyer, D. W., Lin, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6241 · Cited by 972 · see citing works
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Burr, M. L., Sparbier, C. E., Chan, Y.-C., Williamson, J. C., Woods, K., Beavis, P. A., Lam, E. Y. N., Henderson, M. A., Bell, C. C., Stolzenburg, S., et al. (2017) · Nature · doi:10.1038/nature23643 · Cited by 946 · see citing works
The interplay of histone modifications – writers that read
Zhang, T., Cooper, S., & Brockdorff, N. (2015) · EMBO Reports · doi:10.15252/embr.201540945 · Cited by 809 · see citing works
Ubiquitination and selective autophagy
Shaid, S., Brandts, C. H., Serve, H., & Dikic, I. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.72 · Cited by 800 · see citing works
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.4482 · Cited by 796 · see citing works
Deubiquitination and Stabilization of PD-L1 by CSN5
Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793 · see citing works
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785 · see citing works
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Cha, J., Yang, W., Xia, W., Wei, Y., Chan, L.-C., Lim, S., Li, C.-W., Kim, T., Chang, S.-S., Lee, H., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.030 · Cited by 771 · see citing works
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells
Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0992 · Cited by 767 · see citing works
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 756 · see citing works
Self-citationImmune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akinleye, A., & Rasool, Z. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0779-5 · Cited by 743 · see citing works
BRD4 and Cancer: going beyond transcriptional regulation
Donati, B., Lorenzini, E., & Ciarrocchi, A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0915-9 · Cited by 713 · see citing works
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Sato, H., Niimi, A., Yasuhara, T., Permata, T. B. M., Hagiwara, Y., Isono, M., Nuryadi, E., Sekine, R., Oike, T., Kakoti, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01883-9 · Cited by 710 · see citing works
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Mezzadra, R., Sun, C., Jae, L. T., Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M. E. W., Slagter, M., Rozeman, E. A., Hofland, I., et al. (2017) · Nature · doi:10.1038/nature23669 · Cited by 697 · see citing works
Zhao, P., Li, L., Jiang, X., & Li, Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0738-1 · Cited by 682 · see citing works
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653 · see citing works
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Kataoka, K., Shiraishi, Y., Takeda, Y., Sakata, S., Matsumoto, M., Nagano, S., Maeda, T., Nagata, Y., Kitanaka, A., Mizuno, S., et al. (2016) · Nature · doi:10.1038/nature18294 · Cited by 647 · see citing works
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00550 · Cited by 606 · see citing works
Lisberg, A., Cummings, A., Goldman, J. W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.035 · Cited by 580 · see citing works
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
Yao, H., Lan, J., Li, C., Shi, H., Brosseau, J., Wang, H., Lu, H., Fang, C., Zhang, Y., Liang, L., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0375-6 · Cited by 572 · see citing works
Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30144-x · Cited by 568 · see citing works
Teicher, B. A. (1994) · Cancer and Metastasis Reviews · doi:10.1007/bf00689633 · Cited by 563 · see citing works
Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536 · see citing works
Is H3K4me3 instructive for transcription activation?
Howe, F. S., Fischl, H., Murray, S. C., & Mellor, J. (2016) · BioEssays · doi:10.1002/bies.201600095 · Cited by 515 · see citing works
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Yuan, J., Dong, X., Yap, J., & Hu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00949-4 · Cited by 500 · see citing works
Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J., & Hodi, F. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2731 · Cited by 485 · see citing works
PD-L1 Expression in Lung Cancer
Yu, H., Boyle, T. A., Zhou, C., Rimm, D. L., & Hirsch, F. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.014 · Cited by 482 · see citing works
Enhanced Histone Acetylation and Transcription: A Dynamic Perspective
Clayton, A. L., Hazzalin, C. A., & Mahadevan, L. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.017 · Cited by 465 · see citing works
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Han, H., Jain, A. D., Truica, M. I., Izquierdo-Ferrer, J., Anker, J. F., Lysy, B., Sagar, V., Luan, Y., Chalmers, Z. R., Unno, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.001 · Cited by 461 · see citing works
ALK in Lung Cancer: Past, Present, and Future
Shaw, A. T., & Engelman, J. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5353 · Cited by 458 · see citing works
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
Woods, D. M., Sodré, A. L., Villagra, A., Sarnaik, A., Sotomayor, E. M., & Weber, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0077-t · Cited by 454 · see citing works
Liu, J., Fan, L., Yu, H., Zhang, J., He, Y., Feng, D., Wang, F., Li, X., Liu, Q., Li, Y., et al. (2019) · Hepatology · doi:10.1002/hep.30607 · Cited by 449 · see citing works
Ota, K., Azuma, K., Kawahara, A., Hattori, S., Iwama, E., Tanizaki, J., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0016 · Cited by 438 · see citing works
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
Hsu, J.-M., Xia, W., Hsu, Y.-H., Chan, L.-C., Yu, W.-H., Cha, J., Chen, C., Liao, H.-W., Kuo, C., Khoo, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04313-6 · Cited by 437 · see citing works
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
Zhu, H., Bengsch, F., Svoronos, N., Rutkowski, M. R., Bitler, B. G., Allegrezza, M. J., Yokoyama, Y., Kossenkov, A. V., Bradner, J. E., Conejo-Garcia, J. R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.032 · Cited by 435 · see citing works
Li, H., Chiappinelli, K. B., Guzzetta, A. A., Easwaran, H., Yen, R.-W. C., Vatapalli, R. J., Topper, M. J., Luo, J., Connolly, R. M., Azad, N. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1782 · Cited by 428 · see citing works
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Drilon, A. E. D. C., Cappuzzo, F., Ou, S. I., & Camidge, D. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.014 · Cited by 393 · see citing works
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 385 · see citing works
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
Comoglio, P. M., Trusolino, L., & Boccaccio, C. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0002-y · Cited by 380 · see citing works
Zhang, Y., Velez-Delgado, A., Mathew, E., Li, D., Mendez, F., Flannagan, K., Rhim, A. D., Simeone, D. M., Beatty, G. L., & di Magliano, M. P. (2016) · Gut · doi:10.1136/gutjnl-2016-312078 · Cited by 338 · see citing works
What does PD-L1 positive or negative mean?
Ribas, A., & Hu‐Lieskovan, S. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20161462 · Cited by 338 · see citing works
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Atefi, M. S., Avramis, E. V., Lassen, A., Wong, D. J. L., Robert, L., Foulad, D. S., Cerniglia, M., Titz, B., Chodon, T., Graeber, T. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2797 · Cited by 335 · see citing works
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.
Chan, L.-C., Li, C.-W., Xia, W., Hsu, J.-M., Lee, H.-H., Cha, J.-H., Wang, H.-L., Yang, W.-H., Yen, E.-Y., Chang, W.-C., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126022 · Cited by 332 · see citing works
Wang, X., Yang, L., Huang, F., Zhang, Q., Liu, S., Ma, L., & You, Z. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.02.006 · Cited by 327 · see citing works
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
Song, T. L., Nairismägi, M.-L., Laurensia, Y., Lim, J.-Q., Tan, J., Li, Z.-M., Pang, W.-L., Kizhakeyil, A., Wijaya, G.-C., Huang, D.-C., et al. (2018) · Blood · doi:10.1182/blood-2018-01-829424 · Cited by 326 · see citing works
Haddadi, N., Lin, Y., Travis, G., Simpson, A. M., Nassif, N. T., & McGowan, E. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0803-3 · Cited by 314 · see citing works
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
Peng, S., Wang, R., Zhang, X., Ma, Y., Zhong, L., Li, K., Nishiyama, A., Arai, S., Yano, S., & Wang, W. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1073-4 · Cited by 314 · see citing works
Wang, X., Li, J., Dong, K., Fang, L., Long, M., Ouyang, Y., Wei, J., Chen, X., Weng, Y., He, T., et al. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.12.003 · Cited by 313 · see citing works
Hogg, S. J., Vervoort, S. J., Deswal, S., Ott, C. J., Li, J., Cluse, L. A., Beavis, P. A., Darcy, P. K., Martin, B. P., Spencer, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.011 · Cited by 308 · see citing works
Twa, D. D. W., Chan, F. C., Ben‐Neriah, S., Woolcock, B. W., Mottok, A., Tan, K. L., Slack, G. W., Gunawardana, J., Lim, R. S., McPherson, A., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535443 · Cited by 302 · see citing works
Bi, X.-W., Wang, H., Zhang, W.-W., Wang, J., Liu, W.-J., Xia, Z.-J., Huang, H.-Q., Jiang, W., Zhang, Y. J., & Wang, L. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0341-7 · Cited by 297 · see citing works
Zerdes, I., Matikas, A., Bergh, J. C. S., Rassidakis, G. Z., & Foukakis, T. (2018) · Oncogene · doi:10.1038/s41388-018-0303-3 · Cited by 295 · see citing works
Xu, S., Tao, Z., Hai, B., Liang, H., Shi, Y. Q., Wang, T., Song, W., Chen, Y., Ouyang, J., Chen, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11406 · Cited by 290 · see citing works
Palmitoylation stabilizes PD-L1 to promote breast tumor growth
Yang, Y., Hsu, J.-M., Sun, L., Chan, L.-C., Li, C., Hsu, J. L., Wei, Y., Xia, W., Hou, J., Qiu, Y., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0124-5 · Cited by 278 · see citing works
Meng, L., Cheng, Y., Tong, X., Gan, S., Ding, Y., Zhang, Y., Wang, C., Xu, L., Zhu, Y., Wu, J., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b03590 · Cited by 269 · see citing works
Self-citationThe MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
Lu, C., Paschall, A. V., Shi, H., Savage, N. M., Waller, J. L., Sabbatini, M. E., Oberlies, N. H., Pearce, C. J., & Liu, K. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw283 · Cited by 264 · see citing works
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
Jin, X., Ding, D., Yan, Y., Li, H., Wang, B., Ma, L., Ye, Z., Ma, T., Wu, Q., Rodrigues, D. N., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.10.034 · Cited by 261 · see citing works
The role of cancer-derived microRNAs in cancer immune escape
Yi, M., Xu, L., Jiao, Y., Luo, S., Li, A., & Wu, K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00848-8 · Cited by 221 · see citing works
Self-citationShen, M., Xu, Z., Xu, W., Jiang, K., Zhang, F., Ding, Q., Xu, Z., & Chen, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1161-8 · Cited by 215 · see citing works
Lamano, J. B., Lamano, J. B., Li, Y. D., DiDomenico, J. D., Choy, W., Veliceasa, D., Oyon, D. E., Fakurnejad, S., Ampie, L., Kesavabhotla, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2402 · Cited by 209 · see citing works
Roux, C., Jafari, S. M., Shinde, R. S., Duncan, G. S., Cescon, D. W., Silvester, J., Chu, M. F., Hodgson, K., Berger, T., Wakeham, A. C., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819473116 · Cited by 208 · see citing works
Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
Emran, A. A., Chatterjee, A., Rodger, E. J., Tiffen, J. C., Gallagher, S. J., Eccles, M. R., & Hersey, P. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.004 · Cited by 205 · see citing works
Asgarova, A., Asgarov, K., Godet, Y., Peixoto, P., Nadaradjane, A., Boyer‐Guittaut, M., Galaine, J., Guenat, D., Mougey, V., Perrard, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1423170 · Cited by 198 · see citing works
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1
Li, H., Li, C., Li, X., Ding, Q., Guo, L., Liu, S., Liu, C., Lai, C., Hsu, J.-M., Dong, Q., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.252 · Cited by 188 · see citing works
Yao, X., Tu, Y., Xu, Y., Guo, Y., Yao, F., & Zhang, X. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15367 · Cited by 185 · see citing works
EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
Xiao, G., Jin, L.-L., Liu, C., Wang, Y., Meng, Y.-M., Zhou, Z., Chen, J., Yu, X.-J., Zhang, Y., Xu, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0784-9 · Cited by 182 · see citing works
David, J. M., Dominguez, C., McCampbell, K. K., Gulley, J. L., Schlom, J., & Palena, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1349589 · Cited by 180 · see citing works
Ikeda, S., Okamoto, T., Okano, S., Umemoto, Y., Tagawa, T., Morodomi, Y., Kohno, M., Shimamatsu, S., Kitahara, H., Suzuki, Y., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.010 · Cited by 179 · see citing works
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0592-6 · Cited by 179 · see citing works
Self-citationZhang, W., Liu, Y., Yan, Z., Yang, H., Sun, W. Y., Yao, Y., Chen, Y., & Jiang, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000285 · Cited by 174 · see citing works
Anastasiadou, E., Stroopinsky, D., Alimperti, S., Jiao, A. L., Pyzer, A. R., Cippitelli, C., Pepe, G., Severa, M., Rosenblatt, J. M., Etna, M. P., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0178-x · Cited by 168 · see citing works
IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma
Moon, J. W., Kong, S.-K., Kim, B. S., Kim, H. J., Lim, H., Noh, K., Kim, Y., Choi, J.-W., Lee, J.-H., & Kim, Y.-S. (2017) · Scientific Reports · doi:10.1038/s41598-017-18132-0 · Cited by 162 · see citing works
MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells
Stutvoet, T. S., Kol, A., de Vries, E. G. E., de Bruyn, M., Fehrmann, R. S. N., van Scheltinga, A. G. T. T., & de Jong, S. (2019) · The Journal of Pathology · doi:10.1002/path.5280 · Cited by 162 · see citing works
miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity
Jia, L., Xi, Q., Wang, H., Zhang, Z., Liu, H., Cheng, Y., Guo, X., Zhang, J., Zhang, Q., Zhang, L., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.074 · Cited by 159 · see citing works
MiR-873/PD-L1 axis regulates the stemness of breast cancer cells
Gao, L., Guo, Q., Li, X., Yang, X., Ni, H., Wang, T., Zhao, Q., Liu, H., Xing, Y., Xi, T., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.034 · Cited by 156 · see citing works
IL-27 induces the expression of IDO and PD-L1 in human cancer cells
Carbotti, G., Barisione, G., Airoldi, I., Mezzanzanica, D., Bagnoli, M., Ferrero, S., Petretto, A., Fabbi, M., & Ferrini, S. (2015) · Oncotarget · doi:10.18632/oncotarget.6530 · Cited by 147 · see citing works
Glycosylation Changes in Brain Cancer
Veillon, L. J., Fakih, C., Abou‐El‐Hassan, H., Kobeissy, F. H., & Mechref, Y. S. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00271 · Cited by 141 · see citing works
Dong, P., Xiong, Y., Yu, J., Chen, L., Tang, T., Song, Y., Hanley, S. J. B., Yue, J., Watari, H., & Sakuragi, N. (2018) · Oncogene · doi:10.1038/s41388-018-0347-4 · Cited by 132 · see citing works
Xu, L., Chen, X., Shen, M., Yang, D., Fang, L., Weng, G., Tsai, Y., Keng, P. C., Chen, Y., & Lee, S. O. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12135 · Cited by 129 · see citing works
Self-citationMUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer
Bouillez, A., Rajabi, H. N., Jin, C., Samur, M., Tagde, A., Alam, M., Hiraki, M., Maeda, T., Hu, X., Adeegbe, D. O., et al. (2017) · Oncogene · doi:10.1038/onc.2017.47 · Cited by 120 · see citing works
Wang, W. J., Chapman, N. M., Zhang, B., Li, M., Fan, M., Laribee, R. N., Zaidi, M. R., Pfeffer, L. M., Chi, H., & Wu, Z. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3134 · Cited by 119 · see citing works
Deng, S., Hu, Q., Zhang, H., Yang, F., Peng, C., & Huang, C. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1068 · Cited by 116 · see citing works
Ashizawa, M., Okayama, H., Ishigame, T., Min, A. K. T., Saito, K., Ujiie, D., Murakami, Y., Kikuchi, T., Nakayama, Y., Noda, M., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0831 · Cited by 115 · see citing works
Functional loss of ARID1A is tightly associated with high PD‐L1 expression in gastric cancer
Kim, Y., Ahn, J. M., Bae, W. J., Sung, C. O., & Lee, D. (2019) · International Journal of Cancer · doi:10.1002/ijc.32140 · Cited by 113 · see citing works
MYC expression correlates with PD-L1 expression in non-small cell lung cancer
Kim, E. Y., Kim, A., Kim, S. K., & Chang, Y. S. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.006 · Cited by 112 · see citing works
Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
George, J., Saito, M., Tsuta, K., Iwakawa, R., Shiraishi, K., Scheel, A. H., Uchida, S., WATANABE, S.-I. I., Nishikawa, R., Noguchi, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1069 · Cited by 109 · see citing works
Yan, Y., Zheng, L., Du, Q., Yan, B., & Geller, D. A. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02586-9 · Cited by 104 · see citing works
Sun, C., Lan, P., Han, Q., Huang, M., Zhang, Z., Xu, G., Song, J., Wang, J., Wei, H., Zhang, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03584-3 · Cited by 102 · see citing works
A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma
D’Arrigo, P., Russo, M., Rea, A., Tufano, M., Guadagno, E., De, M. D. B., Pacelli, R., Hausch, F., Staibano, S., Ilardi, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19309 · Cited by 100 · see citing works
Wang, H., Fu, C., Du, J., Wang, H., He, R., Yin, X., Li, H., Li, X., Wang, H., Li, K., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-1536-x · Cited by 94 · see citing works
Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma
Chatterjee, A., Rodger, E. J., Ahn, A., Stockwell, P. A., Parry, M. F., Motwani, J., Gallagher, S. J., Shklovskaya, E., Tiffen, J. C., Eccles, M. R., et al. (2018) · iScience · doi:10.1016/j.isci.2018.05.021 · Cited by 87 · see citing works
PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients
Goltz, D., Gevensleben, H., Dietrich, J., & Dietrich, D. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1257454 · Cited by 86 · see citing works
Garassino, M. C., Gelibter, A. J., Grossi, F., Chiari, R., Parra, H. J. S., Cascinu, S., Cognetti, F., Turci, D., Blasi, L., Bengala, C., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.025 · Cited by 85 · see citing works
Crosstalk of intracellular post-translational modifications in cancer
Wu, Z., Huang, R., & Yuan, L. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108138 · Cited by 81 · see citing works
MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC
Xie, W., Liang, L., Wu, K.-G., Wang, L.-X., He, X., Song, C., Wang, Y., & Li, Y. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000488634 · Cited by 80 · see citing works
Self-citationTang, D., Zhao, D., Wu, Y., Yao, R., Zhou, L., Lu, L., Gao, W., & Sun, Y. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13657 · Cited by 80 · see citing works
NI, X. Y., Sui, H. X., Liu, Y., Ke, S. Z., Wang, Y. N., & GAO, F. G. (2012) · Oncology Reports · doi:10.3892/or.2012.1822 · Cited by 79 · see citing works
LPS promotes the expression of PD‐L1 in gastric cancer cells through NF‐κB activation
Li, H., Xia, J., Zhu, F., Xi, Z., Pan, C., Gu, L., & Tian, Y. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27329 · Cited by 79 · see citing works
PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival
Micevic, G., Thakral, D., McGeary, M. K., & Bosenberg, M. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12745 · Cited by 77 · see citing works
TNF-α and TGF-β Counter-Regulate PD-L1 Expression on Monocytes in Systemic Lupus Erythematosus
Ou, J.-N., WIEDEMAN, A. E., & Stevens, A. M. (2012) · Scientific Reports · doi:10.1038/srep00295 · Cited by 75 · see citing works
Shen, M., Xu, L. J., Li, Y., Tsai, Y., Keng, P. C., Chen, Y., Lee, S. O., & Chen, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.19193 · Cited by 73 · see citing works
Self-citationChen, M., Pockaj, B. A., Andreozzi, M., Barrett, M. T., Krishna, S., Eaton, S., Niu, R., & Anderson, K. S. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.05.006 · Cited by 72 · see citing works
Jiang, C., Yuan, F., Wang, J., & Wu, L. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.12.002 · Cited by 69 · see citing works
Shi, Y., Fu, Y., Xin, Z., Zhao, G., Yao, Y., Guo, Y., Ma, G., Bai, S., & Li, H. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02653-1 · Cited by 69 · see citing works
Quandt, D., Jasinski‐Bergner, S., Müller, U., Schulze, B., & Seliger, B. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-151 · Cited by 68 · see citing works
Yoon, C. J., Chang, M. S., Kim, D. H., Kim, W. K., Koo, B. K., Yun, S., Kim, S., Kim, Y. S., & Woo, J. H. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01059-3 · Cited by 67 · see citing works
Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
Pan, Y., Fei, Q., Xiong, P., Yang, J., Zhang, Z., Lin, X., Pan, M., Lu, F., & Huang, H. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1581529 · Cited by 66 · see citing works
Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity
Shi, X., Zhang, D., Li, F., Zhang, Z., Wang, S., Xuan, Y., Yü, P., & Zhang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0831-5 · Cited by 63 · see citing works
Franzen, A., Vogt, T. J., Müller, T., Dietrich, J., Schröck, A., Golletz, C., Brossart, P., Bootz, F., Landsberg, J., Kristiansen, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23080 · Cited by 60 · see citing works
MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma
Qu, F., Ye, J., Pan, X., Wang, J., Gan, S., Chu, C., Chu, J., Zhang, X., Liu, M., He, H., et al. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1479755 · Cited by 60 · see citing works
Sheng, Q., Zhang, Y., Wang, Z.-H., Ding, J., Song, Y., & Zhao, W. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13406 · Cited by 55 · see citing works
Albitar, M. X., Sudarsanam, S., Ma, W., Jiang, S., Chen, W., Funari, V. A., Blocker, F., & Agersborg, S. S. (2018) · Oncotarget · doi:10.18632/oncotarget.24455 · Cited by 54 · see citing works
MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells
Zou, J., Zhuang, M., Yu, X., Li, N., Mao, R., Wang, Z., Wang, J., Wang, X., Zhou, H., Zhang, L., et al. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.07.006 · Cited by 54 · see citing works
Yao, S., Jiang, L., Moser, E. K., Jewett, L., Wright, J., Du, J., Zhou, B., Davis, S. D., Krupp, N. L., Braciale, T. J., et al. (2014) · Mucosal Immunology · doi:10.1038/mi.2014.106 · Cited by 53 · see citing works
Suh, K. J., Sung, J. H., Kim, J. W., Han, S.-H., Lee, H. S., Min, A., Kang, M. H., Kim, J. E., Kim, J., Kim, S. H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19194 · Cited by 49 · see citing works
Shen, J., Li, S., Medeiros, L. J., Lin, P., Wang, S. A., Tang, G., Yin, C. C., You, M. J., Khoury, J. D., Iyer, S. P., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0336-3 · Cited by 48 · see citing works
Sellam, L.-S., Zappasodi, R., Chettibi, F., Djennaoui, D., mesbah, N. Y. A., Amir, Z.-C., Touil–Boukoffa, C., Ouahioune, W., Merghoub, T., & Bourouba, M. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108479 · Cited by 48 · see citing works
MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1
Sun, J., Zhang, X., & Zhang, Y. (2019) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-019-0190-9 · Cited by 47 · see citing works
Ahn, H. K., Kim, S., Kwon, D., Koh, J., Kim, Y. A., Kim, K., Chung, D. H., & Jeon, Y. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174287 · Cited by 46 · see citing works
C-Myc regulates PD-L1 expression in esophageal squamous cell carcinoma.
Liang, M., Yu, F., & Chen, C. (2020) · PubMed Central · Cited by 42 · see citing works
Starke, A., Wuthrich, R. P., & Waeckerle‐Men, Y. (2007) · Nephron Experimental Nephrology · doi:10.1159/000106506 · Cited by 36 · see citing works
Liu, Z., Wen, J., Wu, C., Hu, C., Wang, J., Bao, Q., Wang, H., Wang, J., Zhou, Q., Li, W., et al. (2020) · Aging · doi:10.18632/aging.102679 · Cited by 36 · see citing works
Demuth, C., Andersen, M. N., Jakobsen, K. R., Madsen, A. T., & Sørensen, B. S. (2017) · Oncotarget · doi:10.18632/oncotarget.19920 · Cited by 35 · see citing works
PD-L1 Expression Is Regulated By NF-κB During EMT Signaling In Gastric Carcinoma
Xu, D., Li, J., Li, R., Lan, T., Xiao, C., & Gong, P. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224053 · Cited by 34 · see citing works
Blazanin, N., Cheng, T., Carbajal, S., & DiGiovanni, J. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23073 · Cited by 33 · see citing works
Yang, K., Zhou, J., Chen, Y., Chen, Y., Chen, L., Zhang, P., Ma, L., Jiang, Z., Bian, J., & Yin, W. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106507 · Cited by 33 · see citing works
Huang, T.-Y., Chang, T., Chin, Y., Pan, Y.-S., Chang, W.-J., Liu, F., Hastuti, E. D., Chiu, S.-J., Wang, S.-H., Changou, C. A., et al. (2020) · Cells · doi:10.3390/cells9081830 · Cited by 31 · see citing works
Mimura, K., Kua, L., Shiraishi, K., Siang, L. K., Shabbir, A., Komachi, M., Suzuki, Y., Nakano, T., Yong, W. P., So, J. B. Y., et al. (2014) · Cancer Science · doi:10.1111/cas.12503 · Cited by 30 · see citing works
Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines
Fiedler, M., Schulz, D., Piendl, G., Brockhoff, G., Eichberger, J., Menevse, A. N., Beckhove, P., Hautmann, M., Reichert, T. E., Ettl, T., et al. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112259 · Cited by 19 · see citing works
Zhu, T., Hu, Z., Wang, Z., Ding, H., Li, R., Sun, J., & Wang, G. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106245 · Cited by 15 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works
Self-citationRegulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 850 · see citing works
Self-citationTargeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 491 · see citing works
Self-citationImmune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 424 · see citing works
Breast cancer heterogeneity and its implication in personalized precision therapy
Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., Zheng, Q., Chen, C., & Sun, S. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00363-1 · Cited by 355 · see citing works
Tumor organoids: applications in cancer modeling and potentials in precision medicine
Xu, H., Jiao, D., Liu, A., & Wu, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01278-4 · Cited by 286 · see citing works
Self-citationEmerging phagocytosis checkpoints in cancer immunotherapy
Liu, Y., Wang, Y., Yang, Y., Weng, L., Wu, Q., Zhang, J., Zhao, P., Fang, L., Shi, Y., & Wang, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01365-z · Cited by 287 · see citing works
Cancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 286 · see citing works
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment
Yu, W., Lei, Q., Yang, L., Qin, G., Liu, S., Wang, D., Ping, Y., & Zhang, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01200-4 · Cited by 272 · see citing works
The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia
Ding, X., Wang, L., Zhang, X., Xu, J., Li, P., Liang, H. L., Zhang, X., Xie, L., Zhou, Z., Yang, J., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01102-5 · Cited by 243 · see citing works
Peptides as multifunctional players in cancer therapy
Vadevoo, S. M. P., Gurung, S., Lee, H., Gunassekaran, G. R., Lee, S.-M., Yoon, J., Lee, Y.-K., & Lee, B.-H. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01016-x · Cited by 235 · see citing works
Yi, M., Zhang, J., Li, A., Niu, M., Yan, Y., Jiao, Y., Luo, S., Zhou, P., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01045-x · Cited by 233 · see citing works
Self-citationChronic inflammation, cancer development and immunotherapy
Wen, Y., Zhu, Y., Zhang, C., Yang, X., Gao, Y., Li, M., Yang, H., Liu, T., & Tang, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1040163 · Cited by 231 · see citing works
Yan, Y., Huang, L., Liu, Y., Yi, M., Chu, Q., Jiao, D., & Wu, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01322-3 · Cited by 222 · see citing works
Self-citationPD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Parvez, A., Choudhary, F., Mudgal, P., Khan, R., Qureshi, K. A., Farooqi, H., & Aspatwar, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296341 · Cited by 216 · see citing works
Huang, Z., Zhang, X., Zhang, L., Liu, L., Zhang, J., Sun, Y., Xu, J., Liu, Q., & Long, Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01605-2 · Cited by 215 · see citing works
Cancer combination therapies by angiogenesis inhibitors; a comprehensive review
Ansari, M. J., Bokov, D., Markov, A., Jalil, A. T., Shalaby, M. N., Suksatan, W., Chupradit, S., AL-Ghamdi, H. S., Shomali, N., Zamani, A., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00838-y · Cited by 197 · see citing works
The molecular mechanism and therapeutic landscape of copper and cuproptosis in cancer
Guo, Z., Chen, D., Yao, L., Sun, Y., Li, D., Le, J., Dian, Y., Zeng, F., Chen, X., & Deng, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02192-0 · Cited by 201 · see citing works
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185 · see citing works
Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade
Jin, Z., & Sinicrope, F. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02691 · Cited by 170 · see citing works
Jin, M., Fang, J., Peng, J., Wang, X., Xing, P., Jia, K., Hu, J., Wang, D., Ding, Y., Wang, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02176-8 · Cited by 156 · see citing works
cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment
Zhang, H., Liu, Y., Liu, J., Chen, J., Wang, J., Hua, H. M., & Jiang, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01524-x · Cited by 149 · see citing works
Niu, M., Liu, Y., Yi, M., Jiao, D., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.827921 · Cited by 145 · see citing works
Self-citationTumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future
Warner, A. B., Corrie, P. G., & Hamid, O. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1922 · Cited by 131 · see citing works
Panez-Toro, I., Muñoz-García, J., Vargas-Franco, J. W., Renodon‐Cornière, A., Heymann, M., Lézot, F., & Heymann, D. (2023) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00803-9 · Cited by 132 · see citing works
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Niu, M., Yi, M., Li, N., Luo, S., & Wu, K. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00211-8 · Cited by 125 · see citing works
Self-citationLin, J., Xu, A., Jin, J., Zhang, M., Lou, J., Qian, C., Zhu, J., Wang, Y., Yang, Z., Li, X., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.2024941 · Cited by 124 · see citing works
Yin, Y., Feng, W., Chen, J., Chen, X., Wang, G., Wang, S., Xu, X., Nie, Y., Fan, D., Wu, K., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00539-x · Cited by 119 · see citing works
Self-citationWong, G. L., Manore, S. G., Doheny, D. L., & Lo, H. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.003 · Cited by 109 · see citing works
Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential
Yang, W., Tang, F., Tu, C., Hornicek, F. J., Duan, Z., & Min, L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215887 · Cited by 107 · see citing works
Yu, B., & Ma, W. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.08.006 · Cited by 102 · see citing works
Touchaei, A. Z., & Vahidi, S. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03293-6 · Cited by 102 · see citing works
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Yang, X., Ma, L., Zhang, X., Huang, L., & Wei, J. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00263-4 · Cited by 98 · see citing works
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 94 · see citing works
Self-citationCurrent insight into the regulation of PD-L1 in cancer
Liu, Z., Yu, X., Xu, L., Li, Y., & Zeng, C. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00297-8 · Cited by 93 · see citing works
Self-citationJoo, S., Kim, J., Hong, J., Lahiji, S. F., & Kim, Y. (2022) · Advanced Materials · doi:10.1002/adma.202209966 · Cited by 86 · see citing works
Chen, Z., Zuo, X., Cai, J., Zhang, Y., Han, G., Zhang, L., Ding, W., Wu, J., & Wang, X. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00378-2 · Cited by 88 · see citing works
Li, M., Li, L., Zheng, J., Li, Z., Li, S., Wang, K., & Chen, X. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01745-7 · Cited by 85 · see citing works
Huang, C., Shao, N., Huang, Y., Chen, J., Wang, D., Hu, G., Zhang, H., Luo, L., & Xiao, Z. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100839 · Cited by 87 · see citing works
Alle, M., Sharma, G., Lee, S. H., & Kim, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01402-z · Cited by 80 · see citing works
CAR‐T cell therapy for lung cancer: Potential and perspective
Chen, L., Chen, F., Li, J., Pu, Y., Yang, C., Wang, Y., Lei, Y., & Huang, Y. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14375 · Cited by 77 · see citing works
Immunosuppressive Traits of the Hybrid Epithelial/Mesenchymal Phenotype
Sahoo, S., Nayak, S. P., Hari, K., Purkait, P., Mandal, S., Kishore, A., Levine, H., & Jolly, M. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.797261 · Cited by 74 · see citing works
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Chu, Y., Zhou, X., & Wang, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01097-z · Cited by 75 · see citing works
Xu, J., Zheng, Q., Cheng, X. C., Hu, S., Zhang, C., Zhou, X., Sun, P., Wang, W., Su, Z., Zou, T., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01101-1 · Cited by 71 · see citing works
Latest research progress on anticancer effect of baicalin and its aglycone baicalein
Wang, L., Feng, T., Su, Z., Pi, C., Wei, Y., & Zhao, L. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01397-z · Cited by 75 · see citing works
Stem cell membrane-camouflaged targeted delivery system in tumor
Zhang, W., & Huang, X. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100377 · Cited by 71 · see citing works
Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
Das, A., Tabori, U. Y., Nahum, L. C. S., Collins, N. B., Deyell, R. J., Dvir, R., Faure‐Conter, C., Hassall, T., Minturn, J. E., Edwards, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0411 · Cited by 69 · see citing works
Wang, Q., Wang, J., Yu, D., Zhang, Q., Hu, H., Xu, M., Zhang, H., Tian, S., Zheng, G., Lu, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101357 · Cited by 67 · see citing works
Cai, L., Chen, A., & Tang, D. (2024) · Immunology · doi:10.1111/imm.13785 · Cited by 71 · see citing works
PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
Huang, C., Ren, S., Chen, Y., Liu, A., Wu, Q., Jiang, T., Lv, P., Song, D., Hu, F., Lan, J., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade4186 · Cited by 67 · see citing works
Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives
Sato, Y., Okamoto, K., Kawano, Y., Kasai, A., Kawaguchi, T., Sagawa, T., Sogabe, M., Miyamoto, H., & Takayama, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144646 · Cited by 64 · see citing works
Recent advances and future perspectives in the therapeutics of prostate cancer
Varaprasad, G. L., Gupta, V., Prasad, K., Kim, E., Tej, M. B., Mohanty, P., Verma, H. K., Raju, G. S. R., Bhaskar, L. V., & Huh, Y. S. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00444-9 · Cited by 69 · see citing works
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Li, T., Niu, M., Zhou, J., Wu, K., & Yi, M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01562-5 · Cited by 63 · see citing works
Self-citationRoles of Microvesicles in Tumor Progression and Clinical Applications
Zhu, S., Li, S., Yi, M., Li, N., & Wu, K. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s325448 · Cited by 63 · see citing works
Self-citationMechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1
Mortezaee, K., & Majidpoor, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114824 · Cited by 62 · see citing works
Wang, F., Wu, L., Yin, L., Shi, H. M., Gu, Y., & Xing, N. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.901 · Cited by 60 · see citing works
Yadav, D., Kwak, M., Chauhan, P., Puranik, N., Lee, P. C.-W., & Jin, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.016 · Cited by 58 · see citing works
Liu, Q., Zhang, W., Jiao, R., Lv, Z., Lin, X., Xiao, Y., & Zhang, K. (2022) · Advanced Science · doi:10.1002/advs.202203921 · Cited by 60 · see citing works
Shi, Z., Hu, C., Zheng, X., Sun, C., & Li, Q. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00519-1 · Cited by 60 · see citing works
Yan, J., Liu, D., Wang, J., You, W., Yang, W., Yan, S., & He, W. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101037 · Cited by 59 · see citing works
Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation
Xu, X., Xie, T., Zhou, M., Sun, Y., Wang, F., Tian, Y., Chen, Z., Xie, Y., Wu, R., Cen, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48597-3 · Cited by 59 · see citing works
Advances of Targeted Therapy for Hepatocellular Carcinoma
Niu, M., Yi, M., Li, N., Wu, K., & Wu, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719896 · Cited by 57 · see citing works
Self-citationPD-L1 regulation revisited: impact on immunotherapeutic strategies
Lucibello, G., Mograbi, B., Milano, G. A., Hofman, P. M., & Brest, P. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.06.005 · Cited by 56 · see citing works
Yang, H., Yan, M., Li, W., & Xu, L. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03342-6 · Cited by 56 · see citing works
Self-citationLi, Y., Wang, Z., Gao, P., Cao, D., Dong, R., Zhu, M., Fei, Y., Zuo, X., & Cai, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05498-9 · Cited by 55 · see citing works
Liu, K., Sun, Q., Liu, Q., Li, H., Zhang, W., & Sun, C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113618 · Cited by 54 · see citing works
Morimoto, K., Uchino, J., Yokoi, T., Kijima, T., Gotô, Y., Nakao, A., Hibino, M., Takeda, T., Yamaguchi, H., Takumi, C., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1950411 · Cited by 49 · see citing works
Revisiting PD-1/PD-L pathway in T and B cell response: Beyond immunosuppression
Lu, J., Wu, J., Mao, L., Xu, H., & Wang, S. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.003 · Cited by 49 · see citing works
Guo, X.-J., Lu, J., Zeng, H., Zhou, R., Sun, Q., Yang, G., Pei, Y.-Z., Meng, X., Shen, Y., Zhang, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.705378 · Cited by 48 · see citing works
Combination Therapies for the Optimisation of Bispecific T-Cell Engagers in Cancer Treatment
Zhu, W. M., & Middleton, M. R. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad013 · Cited by 46 · see citing works
Altorki, N. K., Borczuk, A., Harrison, S. W., Groner, L. K., Bhinder, B., Mittal, V., Elemento, O., & McGraw, T. E. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110639 · Cited by 46 · see citing works
Zhu, P., Jin, Z., Kang, G., Jia, Y., Liu, D., Zhang, Q., Guo, F., Jia, Y., Jiao, Y., Li, J., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00934-z · Cited by 46 · see citing works
Therapeutic Targeting of MYC in Head and Neck Squamous Cell Carcinoma
Liu, S., Qin, Z., Mao, Y., Zhang, W., Wang, Y., Jia, L., & Peng, X. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2130583 · Cited by 46 · see citing works
Yahata, T., Ibrahim, A. A., Fujimura, T., Uno, T., Terada, T., Hirano, K.-I., Hosokawa, H., Ohta, A., Miyata, T., & Ando, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1365894 · Cited by 47 · see citing works
Wozniaková, M., Škarda, J., & Raška, M. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610502 · Cited by 44 · see citing works
Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance
Popovic, A., & Tartare‐Deckert, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924553 · Cited by 42 · see citing works
Park, J. C., Krishnakumar, H. N., & Saladi, S. V. (2022) · Current Oncology · doi:10.3390/curroncol29060334 · Cited by 42 · see citing works
Dai, Y., Wu, J., Wang, J., Wang, H., Guo, B., Jiang, T., Cai, Z., Han, J., Zhang, H., Xu, B., et al. (2024) · Small · doi:10.1002/smll.202311344 · Cited by 42 · see citing works
Jiang, A., Wang, J., Liu, N., Zheng, X., Li, Y., Ma, Y., Zheng, H., Chen, X., Fan, C., Zhang, R., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.833797 · Cited by 42 · see citing works
A new era in cancer treatment: harnessing ZIF-8 nanoparticles for PD-1 inhibitor delivery
Rastin, F., Oryani, M. A., Iranpour, S., Javid, H., Hashemzadeh, A., & Karimi‐Shahri, M. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb02471g · Cited by 41 · see citing works
Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer
Ri, M., Ma, J., & Jin, X. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114370 · Cited by 41 · see citing works
Engineered Extracellular Vesicles: Emerging Therapeutic Strategies for Translational Applications
Ziegler, J. N., & Tian, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015206 · Cited by 40 · see citing works
Cancer immunotherapies: A hope for the uncurable?
Hamdan, F., & Cerullo, V. (2023) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1140977 · Cited by 40 · see citing works
Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
Yiong, C. S., Lin, T. P., Lim, V., Toh, T. B., & Yang, V. S. (2023) · Biomarker Research · doi:10.1186/s40364-023-00513-5 · Cited by 39 · see citing works
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers
Strati, A. D., Adamopoulos, C., Kotsantis, I., Psyrri, A. K., Lianidou, E. S., & Papavassiliou, A. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031235 · Cited by 41 · see citing works
The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer
Aghbash, P. S., Hemmat, N., Baradaran, B., Mokhtarzadeh, A., Poortahmasebi, V., Oskouee, M. A., & Baghi, H. B. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.026776 · Cited by 38 · see citing works
Long, S., Huang, G., Ouyang, M., Xiao, K., Zhou, H., Hou, A., Li, Z., Zhong, Z., Zhong, D., Wang, Q., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05878-x · Cited by 38 · see citing works
Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands
Kamali, A. N., Bautista, J. M., Eisenhut, M., & Hamedifar, H. (2023) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355231192043 · Cited by 38 · see citing works
Su, X., Li, J., Xu, X., Ye, Y., Wang, C., Pang, G., Liu, W., Liu, A., Zhao, C., & Hao, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05552-6 · Cited by 41 · see citing works
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy
Li, X.-M., Zhao, Z., Xiao, Y., Xia, Q., Zhou, P., Wang, S., Wu, H., & Hu, J. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00394-2 · Cited by 38 · see citing works
Cancer immunoediting hypothesis: history, clinical implications and controversies
Lasek, W. (2022) · Central European Journal of Immunology · doi:10.5114/ceji.2022.117376 · Cited by 39 · see citing works
Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome
Lee, P., Yim, R., Yung, Y., Chu, H.-T., Yip, P.-K., & Gill, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910232 · Cited by 38 · see citing works
Gao, Z., Chen, J., Li, X.-G., Shi, Y., Tang, Z., Liu, W.-R., Zhang, X., Huang, A., Luo, X., Gao, Q., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02550-w · Cited by 37 · see citing works
miR-940 is a new biomarker with tumor diagnostic and prognostic value
Li, H., Li, Y., Tian, D., Zhang, J., & Duan, S. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.05.003 · Cited by 36 · see citing works
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
Li, Z., Sun, G., Sun, G., Cheng, Y., Wu, L., Wang, Q., Lv, C., Zhou, Y., Xia, Y., & Tang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771335 · Cited by 37 · see citing works
Targeting the Macrophage-Ferroptosis Crosstalk: A Novel Insight into Tumor Immunotherapy
Zhou, Z., Xu, B., Hu, N., Guo, Z., Bao, W., Shao, B., & Yang, W. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2707203 · Cited by 36 · see citing works
Song, P., Lu, Z., Jiang, T., Han, W., Chen, X., & Zhao, X. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.09.245 · Cited by 36 · see citing works
RetractedEngineered biological nanoparticles as nanotherapeutics for tumor immunomodulation
Rahmat, J. N., Liu, J., Chen, T., Li, Z., & Zhang, Y. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00602f · Cited by 37 · see citing works
Warmuth, S., Gunde, T., Snell, D. C., Brock, M., Weinert, C., Simonin, A., Hess, C., Tietz, J., Johansson, M. H., Spiga, F. M., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.2004661 · Cited by 35 · see citing works
(Im)maturity in Tumor Ecosystem
Mortezaee, K., & Majidpoor, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.813897 · Cited by 34 · see citing works
- Authors
- Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K.
- Affiliations
- Tongji Hospital (CN)
- Zhengzhou University (CN)
- Corresponding author
- Luo, Suxia
- Wu, Kongming
- Venue
- Journal of Hematology & Oncology
- Published
- 2021-01-07
- Volume
- 14
- Issue
- 1
- Pages
- 10-10
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC7792099
- OpenAlex
- W3118950316
- Cited by
- 681
- References
- 153
- Citations by year
- 2026: 114 · 2025: 108 · 2024: 169 · 2023: 130 · 2022: 113 · 2021: 47
- FWCI
- 13.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81874120, 82073370)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, PD-1/PD-L1 axis, tumor microenvironment, tumor immune evasion, transcriptional regulation, post-transcriptional regulation, post-translational regulation, T cell exhaustion, immune checkpoint inhibitors, predictive biomarkers
- MeSH terms
- Animals, Humans, Neoplasms, Protein Processing, Post-Translational, Transcriptional Activation, Gene Expression Regulation, Neoplastic, Tumor Escape, Epigenesis, Genetic, Tumor Microenvironment, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
